News - Sanofi

Filter

Current filters:

Sanofi

Popular Filters

46 to 70 of 311 results

Sanofi and Regeneron report positive Phase III results with sarilumab in RA

Sanofi and Regeneron report positive Phase III results with sarilumab in RA

22-11-2013

French drug major Sanofi (Euronext: SAN) and US partner Regeneron Pharmaceuticals (Nasdaq: REGN) have…

Anti-Arthritics/RheumaticsEuropeNorth AmericaPharmaceuticalRegeneronResearchSanofisarilumabUSA

BIO-Europe 2013: Nanotechnology innovation and the pharma industry

BIO-Europe 2013: Nanotechnology innovation and the pharma industry

20-11-2013

The future of nanotechnology in pharma has been discussed by the Nanomedicine panel at the BIO-Europe…

AstraZenecaEuropePharmaceuticalResearchSanofi

Following talks with FDA, Sanofi drops fedratinib development

Following talks with FDA, Sanofi drops fedratinib development

18-11-2013

French drug major Sanofi this morning revealed its decision to halt all clinical trials and cancel plans…

fedratinibOncologyPharmaceuticalRegulationResearchSanofi

New products will grow atopic dermatitis market to $5.6 billion by 2022

New products will grow atopic dermatitis market to $5.6 billion by 2022

15-11-2013

Atopic dermatitis therapeutic sales in nine major global markets are forecast to increase from $3.9 billion…

Anacor PharmaceuticalsChinaDermatologicalsdupilumabEuropeIndiaMarkets & MarketingPharmaceuticalRegeneronSanofiUSA

Sanofi’s Lemtrada gets support from FDA advisory panel

Sanofi’s Lemtrada gets support from FDA advisory panel

14-11-2013

French drug major Sanofi (Euronext: SAN) has received support from a US Food and Drug Administration…

CNS DiseasesEuropeGenzymeLemtradaPharmaceuticalRegulationSanofi

Morningstar analysts find GlaxoSmithKline has strongest pipeline

Morningstar analysts find GlaxoSmithKline has strongest pipeline

06-11-2013

Morningstar, an independent Chicago-based investment research firm, recently published the November 2013…

AbbVieAstraZenecaBayerFinancialGlaxoSmithKlineMerck & CoPharmaceuticalResearchSanofi

Sanofi says 3rd-qtr profits down, but sees end to patent cliff period

Sanofi says 3rd-qtr profits down, but sees end to patent cliff period

30-10-2013

French drug major Sanofi this morning posted third-quarter 2013 results with a fall in profitability…

FinancialGenzymePharmaceuticalSanofi

Sanofi Pasteur MSD first vaccine company in pilot for rapid European HTA

17-10-2013

Sanofi Pasteur MSD, a vaccines joint venture between drug major Sanofi of France’s Sanofi Pasteur…

Merck & CoPharmaceuticalRegulationSanofiSanofi Pasteur MSDVaccinesZostavax

Vaccine confers long-term protection against cholera

17-10-2013

A clinical study published in the Lancet Infectious Diseases demonstrates for the first time that an…

PharmaceuticalSanofiShanthaTropical diseasesVaccines

Sanofi’s alirocumab monotherapy reduced LDL cholesterol three times more than ezetimibe

Sanofi’s alirocumab monotherapy reduced LDL cholesterol three times more than ezetimibe

16-10-2013

Sanofi and partner Regeneron Pharmaceuticals this morning released results from the Phase III ODYSSEY…

BiotechnologyCardio-vascularPharmaceuticalRegeneronResearchSanofi

Genzyme to invest $80 million to expand capacity for Fabrazyme

Genzyme to invest $80 million to expand capacity for Fabrazyme

15-10-2013

French drug major Sanofi’s US biotech subsidiary Genzyme says that it is investing $80 million to build…

BiotechnologyFabrazymeFinancialGenzymeNorth AmericaProductionRare diseasesSanofi

FDA allows OTC of Sanofi’s Nasacort

FDA allows OTC of Sanofi’s Nasacort

13-10-2013

The US Food and Drug Administration has approved Sanofi’s Nasacort Allergy 24HR nasal spray as an over-the-counter…

ChattemNasacort AQNorth AmericaPharmaceuticalRegulationRespiratory and PulmonarySanofi

Lyxumia plus basal insulin lowers blood sugar, latest data show

Lyxumia plus basal insulin lowers blood sugar, latest data show

05-10-2013

Sanofi has announced new GetGoal-L sub-analysis results showing that reductions in HbA1c with Lyxumia…

DiabetesLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Aubagio significantly reduced risk of new clinical relapse or MRI lesion in MS study

03-10-2013

French drug major Sanofi and its subsidiary Genzyme announced positive new data from the TOPIC study…

AubagioGenzymeNeurologicalPharmaceuticalResearchSanofi

Sanofi and Aviesan renew their agreement to accelerate research in France

Sanofi and Aviesan renew their agreement to accelerate research in France

01-10-2013

Sanofi and Aviesan, the French National Alliance for Life Sciences and Health, have renewed for a period…

EuropePharmaceuticalRare diseasesResearchSanofi

Sanofi strengthens its presence in Algeria with €70 million investment

Sanofi strengthens its presence in Algeria with €70 million investment

26-09-2013

French drug major Sanofi revealed today that construction has begun on its new Sidi Abdellah industrial…

Cardio-vascularDiabetesFinancialPharmaceuticalProductionRest of the WorldSanofi

Geropharm to invest $45 million in Russian insulin production

Geropharm to invest $45 million in Russian insulin production

25-09-2013

Geropharm, one of Russia’s leading pharmaceutical and biotech companies, is establishing a plant for…

DiabetesEli LillyEuropeFinancialGeropharmNovo NordiskPharmaceuticalProductionSanofi

Sanofi reaches deal in rimonabant lawsuit

Sanofi reaches deal in rimonabant lawsuit

23-09-2013

French drug major Sanofi (Euronext; SAN) has reached a $40 million settlement in a US lawsuit accusing…

MetabolicsNorth AmericaRegulationSanofi

Easier access to funded enzyme replacement therapy proposed in New Zealand

20-09-2013

New Zealand’s Pharmaceutical Management Agency PHARMAC is providing greater funded access to the expensive…

Asia-PacificBiotechnologyFinancialGenzymeRare diseasesRelvar ElliptaSanofi

UK's NICE calls for more information on MS treatment Aubagio

18-09-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) is calling on Genzyme,…

AubagioBiotechnologyEuropeGenzymeNeurologicalPharmaceuticalPricingRegulationSanofi

Genzyme's MS drug Lemtrada approved in Europe

17-09-2013

French drug major Sanofi (Euronext: SAN) and its USA-based biotech subsidiary Genzyme revealed this morning…

AubagioBiotechnologyEuropeGenzymeLemtradaNeurologicalPharmaceuticalRegulationSanofi

46 to 70 of 311 results

Back to top